No association between proton pump inhibitor use and ALS risk: a nationwide nested case–control study

Abstract The use of proton pump inhibitors (PPIs) has been proposed as a potential risk factor for neurodegenerative diseases, but little is known regarding its role in amyotrophic lateral sclerosis (ALS). We therefore aimed to assess the association of PPI use with the subsequent risk of ALS, and p...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Hakan Cetin, Jiangwei Sun, Catarina Almqvist, Berthold Reichardt, Matthias Tomschik, Fritz Zimprich, Fang Fang, Caroline Ingre
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2020
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/f9bb24ad6dd747789e8a5deeea35072a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f9bb24ad6dd747789e8a5deeea35072a
record_format	dspace
spelling	oai:doaj.org-article:f9bb24ad6dd747789e8a5deeea35072a2021-12-02T16:34:04ZNo association between proton pump inhibitor use and ALS risk: a nationwide nested case–control study10.1038/s41598-020-70373-82045-2322https://doaj.org/article/f9bb24ad6dd747789e8a5deeea35072a2020-08-01T00:00:00Zhttps://doi.org/10.1038/s41598-020-70373-8https://doaj.org/toc/2045-2322Abstract The use of proton pump inhibitors (PPIs) has been proposed as a potential risk factor for neurodegenerative diseases, but little is known regarding its role in amyotrophic lateral sclerosis (ALS). We therefore aimed to assess the association of PPI use with the subsequent risk of ALS, and performed a register-based nationwide nested case–control study, including 2,484 ALS cases diagnosed during July 2006–December 2013 in Sweden and 10 population controls per case that were individually matched to the case by sex, age, and area of residence. Dispenses and cumulative defined daily doses (cDDDs) of PPIs were extracted from the Swedish Prescribed Drug Register. The association of PPI use with the risk of ALS was assessed using conditional logistic regression, after applying different lag windows to avoid reverse causation. ALS patients were more likely to be dispensed with PPIs before diagnosis than controls. However, previous PPI use was not associated with an increased risk of ALS (OR = 1.08, 95% CI 0.97–1.19), and there was no dose–response relationship between cDDDs of PPIs and ALS risk (p = 0.0874), after excluding dispenses during the year before ALS diagnosis. The results were similar after excluding dispenses during the 2 or 3 years before ALS diagnosis.Hakan CetinJiangwei SunCatarina AlmqvistBerthold ReichardtMatthias TomschikFritz ZimprichFang FangCaroline IngreNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 10, Iss 1, Pp 1-6 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Hakan Cetin Jiangwei Sun Catarina Almqvist Berthold Reichardt Matthias Tomschik Fritz Zimprich Fang Fang Caroline Ingre No association between proton pump inhibitor use and ALS risk: a nationwide nested case–control study
description	Abstract The use of proton pump inhibitors (PPIs) has been proposed as a potential risk factor for neurodegenerative diseases, but little is known regarding its role in amyotrophic lateral sclerosis (ALS). We therefore aimed to assess the association of PPI use with the subsequent risk of ALS, and performed a register-based nationwide nested case–control study, including 2,484 ALS cases diagnosed during July 2006–December 2013 in Sweden and 10 population controls per case that were individually matched to the case by sex, age, and area of residence. Dispenses and cumulative defined daily doses (cDDDs) of PPIs were extracted from the Swedish Prescribed Drug Register. The association of PPI use with the risk of ALS was assessed using conditional logistic regression, after applying different lag windows to avoid reverse causation. ALS patients were more likely to be dispensed with PPIs before diagnosis than controls. However, previous PPI use was not associated with an increased risk of ALS (OR = 1.08, 95% CI 0.97–1.19), and there was no dose–response relationship between cDDDs of PPIs and ALS risk (p = 0.0874), after excluding dispenses during the year before ALS diagnosis. The results were similar after excluding dispenses during the 2 or 3 years before ALS diagnosis.
format	article
author	Hakan Cetin Jiangwei Sun Catarina Almqvist Berthold Reichardt Matthias Tomschik Fritz Zimprich Fang Fang Caroline Ingre
author_facet	Hakan Cetin Jiangwei Sun Catarina Almqvist Berthold Reichardt Matthias Tomschik Fritz Zimprich Fang Fang Caroline Ingre
author_sort	Hakan Cetin
title	No association between proton pump inhibitor use and ALS risk: a nationwide nested case–control study
title_short	No association between proton pump inhibitor use and ALS risk: a nationwide nested case–control study
title_full	No association between proton pump inhibitor use and ALS risk: a nationwide nested case–control study
title_fullStr	No association between proton pump inhibitor use and ALS risk: a nationwide nested case–control study
title_full_unstemmed	No association between proton pump inhibitor use and ALS risk: a nationwide nested case–control study
title_sort	no association between proton pump inhibitor use and als risk: a nationwide nested case–control study
publisher	Nature Portfolio
publishDate	2020
url	https://doaj.org/article/f9bb24ad6dd747789e8a5deeea35072a
work_keys_str_mv	AT hakancetin noassociationbetweenprotonpumpinhibitoruseandalsriskanationwidenestedcasecontrolstudy AT jiangweisun noassociationbetweenprotonpumpinhibitoruseandalsriskanationwidenestedcasecontrolstudy AT catarinaalmqvist noassociationbetweenprotonpumpinhibitoruseandalsriskanationwidenestedcasecontrolstudy AT bertholdreichardt noassociationbetweenprotonpumpinhibitoruseandalsriskanationwidenestedcasecontrolstudy AT matthiastomschik noassociationbetweenprotonpumpinhibitoruseandalsriskanationwidenestedcasecontrolstudy AT fritzzimprich noassociationbetweenprotonpumpinhibitoruseandalsriskanationwidenestedcasecontrolstudy AT fangfang noassociationbetweenprotonpumpinhibitoruseandalsriskanationwidenestedcasecontrolstudy AT carolineingre noassociationbetweenprotonpumpinhibitoruseandalsriskanationwidenestedcasecontrolstudy
_version_	1718383790251835392

No association between proton pump inhibitor use and ALS risk: a nationwide nested case–control study

Ejemplares similares